Taking No Chances in Neuroprotection: Pharmos Applies a Precise Phase III Protocol
This article was originally published in Start Up
Executive Summary
Neuroprotection has been something of a clinical tar pit--many compounds have gone into the clinic but none have emerged. It's hard to know what's going on inside someone else's head, much less measure changes induced by any agent. Pharmos feels it has learned from the missteps of other companies, and so has structured a highly precise Phase III protocol to give its drug candidate dexanabinol the best chance at success.